Overview

SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole

Status:
Withdrawn
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how safe, effective, and well tolerated a new investigational antifungal drug, SUBA-itraconazole, is for patients who have been previously treated with fluconazole and have had either an insufficient response to treatment with fluconazole or a negative reaction to fluconazole preventing their further treatment with it.
Phase:
Phase 2
Details
Lead Sponsor:
George R Thompson
Collaborator:
Mayne Pharma International Pty Ltd
Treatments:
Itraconazole